Drugs / CMP-001
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03507699 | Dec 2018 → Aug 2021 | metastasis from malignant tumor of colon | Sheba Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03438318 | Mar 2018 → Dec 2019 | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03084640 | May 2017 → Jul 2021 | melanoma | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02680184 | Apr 2016 → Dec 2022 | melanoma | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04387071 | Apr 2021 → Dec 2022 | high grade malignant neoplasm, pancreatic adenocarcinoma | University of Southern California | Terminated | No outcome recorded |
| Phase 1/2 | NCT03983668 | Jan 2020 → Aug 2024 | lymphoma | Umar Farooq | Terminated | No outcome recorded |
| Phase 1/2 | NCT02554812 | Nov 2015 → Mar 2023 | cancer of unknown primary site | Pfizer | Terminated | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT04708418 | Oct 2021 → Dec 2026 expected | cutaneous melanoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04807192 | Apr 2021 → Dec 2025 overdue | triple-negative breast carcinoma | Centre Hospitalier Universitaire Vaudois | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04698187 | Mar 2021 → Feb 2024 | metastatic melanoma | Regeneron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04633278 | Jan 2021 → Jan 2024 | head and neck squamous cell carcinoma | Regeneron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03618641 | Aug 2018 → Aug 2020 | lymph node cancer, melanoma | Diwakar Davar | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04695977 | Feb 2021 → Jul 2024 | metastatic melanoma | Regeneron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT05059522 | Sep 2021 → Dec 2026 expected | non-small cell lung carcinoma, ovarian cancer, urothelial carcinoma | Pfizer | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-07-15 | XOMA (US) LLC | XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences xoma.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02554812 ↗ |
| Known as | CYT003 | “CMP-001 (vidutolimod, CYT003, QbG10) has already been shown to increase CD8+ T cell intratumoral infiltration in early clinical data, and ongoing data of a phase Ib clinical...” NCT04807192 ↗ |
| Known as | QbG10 | “CMP-001 (vidutolimod, CYT003, QbG10) has already been shown to increase CD8+ T cell intratumoral infiltration in early clinical data, and ongoing data of a phase Ib clinical...” NCT04807192 ↗ |
| Known as | vidutolimod | “CMP-001 (vidutolimod, CYT003, QbG10) has already been shown to increase CD8+ T cell intratumoral infiltration in early clinical data, and ongoing data of a phase Ib clinical...” NCT04807192 ↗1“Vidutolimod, a CpG-A TLR9 agonist, was investigated in a phase 1b study (CMP-001-003; ClinicalTrials.gov, NCT03438318) in combination with atezolizumab with and without...” PMID 36925644 ↗ Oct 2022 |
| Action | Activate | “TLR9 agonist” NCT02554812 ↗ |
| Modality | Other / unclassified | “Vidutolimod, a CpG-A TLR9 agonist” PMID 36925644 ↗ Oct 2022 |
| Route | Other | “via intratumoral injection” NCT02680184 ↗ |
| Target | TLR9 | “Vidutolimod, a CpG-A TLR9 agonist” PMID 36925644 ↗ Oct 2022 |